Moreover, baseline tumor fraction (TF) can be used as a proxy to estimate disease burden22 and has the potential to improve prediction of NAT outcomes over approaches based on routine clinical staging features alone23, which can be relevant for planning and optimizing the choice of the most appropriate NAT strategy. Here, BRD2 is linked to neoplasm.